HIV-associated lipodystrophy syndrome: A review of clinical aspects

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 16, Issue 4, 2005, Pages 233-243

  Baril, Jean Guy ^a,b,c   Junod, Patrice ^a,b   LeBlanc, Roger ^d,e   Dion, Harold ^f   Therrien, Rachel ^g   Laplante, François ^a   Falutz, Julian ^h   Côté, Pierre ^a,b   Hébert, Marie Nicole ^c   Lalonde, Richard ^e   Lapointe, Normand ⁱ   Lévesque, Dominic ^j   Pinault, Lyse ^k   Rouleau, Danielle ^b   Tremblay, Cécile ^g   Trottier, Benoît ^b,f   Trottier, Sylvie ^l   Tsoukas, Chris ^h   Weiss, Karl ^m  

^a Clinique Medicale du Quartier Latin   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c Ministere de la Sante et des Services Sociaux   (Canada)

^d Clinique Golberg LeBlanc et Rosengren   (Canada)

^e ROYAL VICTORIA HOSPITAL   (Canada)

^f Clinique l'Actuel   (Canada)

^g CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^h MONTREAL GENERAL HOSPITAL   (Canada)

ⁱ UNIVERSITY OF MONTREAL   (Canada)

^j Comité des Personnes Atteintes du VIH du Québec ^*  (Canada)

^k Coalition des Organismes Communautaires Québécois de Lutte Contre le Sida ^*  (Canada)

^l LAVAL UNIVERSITY   (Canada)

^m MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

more..

Author keywords

Adverse events; Antiretroviral drugs; Fat accumulation; HIV infection; Lipoatrophy; Lipodystrophy; Metabolic complications

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABACAVIR; ADEFOVIR; ANABOLIC AGENT; CARNITINE; CYTOKINE; EFAVIRENZ; GUANOSINE DERIVATIVE; HUMAN GROWTH HORMONE; HYDROXYUREA; LAMIVUDINE; METFORMIN; NEVIRAPINE; POLYLACTIC ACID; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THYMIDINE DERIVATIVE; ZIDOVUDINE;

ANTHROPOMETRY; AUTOLOGOUS FAT TRANSFER; AUTOTRANSPLANTATION; BIOLECTRIC IMPEDANCE; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; ECHOGRAPHY; EXERCISE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERINSULINEMIA; HYPERLACTATEMIA; IMPEDANCE; INSULIN RESISTANCE; LIPID STORAGE; LIPOATROPHY; LIPODYSTROPHY; LIPODYSTROPHY SYNDROME; LIPOSUCTION; METABOLIC DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITION; PROSTHESIS; REVIEW; RISK FACTOR; SYMPTOMATOLOGY; SYNDROME; TREATMENT INTERRUPTION;

EID: 25444533063     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2005/303141     Document Type: Review

References (150)

1. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8.
2. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000;14:F25-32.
3. Schambelan M, Benson CA, Carr A, et al; International AIDS Society-USA. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: Recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002;31:257-75.
4. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG; HIV Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: A case-control study. Lancet 2003;361:726-35.
5. Grunfeld C. Basic science and metabolic disturbances. [Abstract TuOr158]. In: Program and abstracts of the XIV International AIDS Conference. Barcelona: Fundació Barcelona SIDA, 2002.
6. Grunfeld C. The FRAM Study [abstract PL9.4]. In: Program and abstracts of the 6th International Congress on Drug Therapy in HIV Infection (Glasgow). London: The Royal Free and University College Medical School; Stockholm: Karolinska Institutet; Amsterdam: Academic Medical Centre, University of Amsterdam; Stockholm: International AIDS Society, 2002:12.
7. Gripshover B, Tien PC, Saag M, Osmond D, Bacchetti P, Grunfield C. Lipoatrophy is the dominant feature of the lipodystrophy syndrome in HIV-infected men [abstract 732]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Virginia: Foundation for Retrovirology and Human Health, 2003:319.
8. Saag M, Tien PC, Gripshover B, Osmond D, Bacchetti P, Grunfield C. Body composition in HIV+ men with and without peripheral lipoatrophy is different than controls [abstract 733]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Virginia: Foundation for Retrovirology and Human Health, 2003:320.
9. Zolopa A, Benson C, Bacchetti P, Tien PC, Grunfeld C; for the investigators of the Fat Redistribution and Metabolic Change in HIV Infection (FRAM) Study. Buffalo hump in men with HIV infection: Larger but not more common [abstract 734]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Virginia: Foundation for Retrovirology and Human Health, 2003:320.
10. Colebunders R, Dreezen C, De Roo A, Florence E, deMey I, Schrooten W; on behalf of the Eurosupport II group. Lipodystrophy in women taking antiretroviral therapy. Antivir Ther 2000;5(Suppl 5):57.
11. Jaquet D, Levine M, Ortega-Rodriguez E, et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 2000;14:2123-8.
12. Beregszasxi M, Blanche S, Dolfus C, et al. Anthropometric assessement and follow-up of lipodystrophy in HIV-infected children. Antivir Ther 2003;8:L60.
13. Piroth L, Grappin M, Petit JM, et al. Incidence of gynecomastia in men infected with HIV and treated with highly active antiretroviral therapy. Scand J Infect Dis 2001;33:559-60.
14. Manfredi R, Calza L, Chiodo F. Gynecomastia, lipodystrophy syndrome, and dyslipidemia occurring or worsening during antiretroviral regimens other than protease inhibitor-based ones. J Acquir Immune Defic Syndr 2004;35:99-102.
15. Garcia-Benayas T, Blanco F, Soriano V, et al. Gynecomastia in HIV infected male: Causes, clinical presentation and outcome. Antivir Ther 2003;8(Suppl 1):S376.
16. Woolley IJ, Mijch AM, Carter VM, Archer B, Hoy JF. Anterior neck fat deposition in lipodystrophy syndrome: A new variant on a theme? AIDS 2003;17:1857-8.
17. Lichtenstein KA, Ward DJ, Moorman AC, et al; HIV Outpatient Study Investigators. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001;15:1389-98.
18. Lichtenstein KA, Delaney KM, Armon C, et al; HIV Outpatient Study Investigators. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003;32:48-56.
19. Miller J, Carr A, Emery S, et al. HIV lipodystrophy: Prevalence, severity and correlates of risk in Australia. HIV Med 2003;4:293-301.
20. Muurahainen N, Glesby M, Falutz J, et al. Different factors are associated with lipohypertrophy and lipoatrophy in HIV patients with fat redistribution. Antivir Ther 2000;5(Suppl 5):65-6.
21. Saves M, Raffi F, Capeau J, et al; Antiproteases Cohorte (APROCO) Study Group. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002;34:1396-405.
22. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study. AIDS 2000;14:37-49.
23. Kingsley L, Smit E, Riddler S, et al. Prevalence of lipodystrophy and metabolic abnormalities in the multicenter AIDS cohort study (MACS), [abstract 538]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Virginia: Foundation for Retrovirology and Human Health, 2001.
24. Shevitz A, Wanke CA, Falutz J, Kotler DP. Clinical perspectives on HIV-associated lipodystrophy syndrome: An update. AIDS 2001;15:1917-30.
25. McComsey G, Maa JF. Host factors may be more important than choice of antiretrovirals in the development of lipoatrophy. AIDS Read 2003;13:539-42,59.
26. Galli M, Cozzi-Lepri A, Gervasoni C, et al; for the LipoICONA Study Group. Triglyceridaemia, but not cholesterolemia and glycemia, is a predictor of lipodystrophy: The results of LipoICONA longitudinal study. Antivir Ther 2002;7:L29.
27. Pewen WF, Calhoun BC, Riddler SA, Kingsley LA. The temporal relationship between lipoatrophy and lipohypertrophy in HIV-associated lipodystrophy. Antivir Ther 2002;7:L65.
28. Mahajan AP, Tashima KT, Bausserman LL, Flynn MM, Carpenter CC. Plateau in body habitus changes and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy: A 3.5-year study. J Acquir Immune Defic Syndr 2001;28:332-5.
29. Miro JM, Martinez E, Garcia F, et al. Incidence of lipodystrophy in patients with primary HIV-1 infection treated with HAART [abstract 12]. In: Program and abstracts of the 7th Conference on Retrovirus and Opportunistic Infections (San Francisco). Virginia: Foundation for Retrovirology and Human Health, 2000:77.
30. Goujard C, Boufassa F, De veau C, Laskri D, and Meyer L; for the Primo Group. Early occurrence of lipodystrophy in HIV-1-infected patients treated during primary infection [abstract 403]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Virginia: Foundation for Retrovirology and Human Health, 2001:163.
31. Mauss S, Berger F, Carls H, Schmutz G. Rapid development of central adiposity after postexposure prophylaxis with antiretroviral drugs: A proof of principle? AIDS 2003;17:944-55.
32. Capeau J, Raffi F, Savès M, et al. Lipodystrophy and metabolic disorders in HIV-infected patients treated by protease inhibitors: Is there an association? Antivir Ther 2000;5(Suppl 5):55.
33. Bernasconi E. Metabolic effects of protease inhibitor therapy. AIDS Read 1999;9:254-6, 259-60, 266-9.
34. Dong LK, Bausserman LL, Flynn MM, et al. Changes in body habitus and serum lipid anormalities in HIV-positive women on HAART. J Acquir Immune Defic Syndr 1999;21:107-13.
35. Goetzenich A, Corzillius M, Mauss S, et al. The impact of lipodystrophy on quality of life [abstract WePpB1381]. In: Program and abstracts of the XIII International AIDS Conference (Durban). Stockholm: International AIDS Society, 2000.
36. Blanch J, Rousaud A, Martinez E, et al. Factors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1. Clin Infect Dis 2004;38:1464-70.
37. Prize G, Guimaraes-Walker A, de Sousa C, Brain C, Kapembwa M, Scullard G. Psychological assessment of patients referred to multidisciplinary lipodystrophy/metabolic clinic [abstract 498]. In: Program and abstracts of the 1st IAS Conference on HIV Pathogenesis and Treatment (Buenos Aires). Stockholm: International AIDS Society, 2001:226.
38. Gallego L, Blanco F, Gordillo V, et al. Mental disorders related to lipodystrophy body shape changes in HIV-positive patients with homosexual risk behavior. Antivir Ther 2000;5(Suppl 5):45. (Abst)
39. Collins EJ, Burgoyne RW, Wagner CA, Halman MH, Walmsley SL. The impact of lipodystrophy on health-related quality of life, body image, mood, self esteem and medication compliance. Antivir Ther 2002;7:L48.
40. Ammassari A, Antinori A, Cozzi-Lepri A, et al. Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr 2002;31:S140-4.
41. Galli M, Veglia F, Angarano G, et al; for the Lipodystrophy Italian Multicenter Study (LIMS). Risk factors associated with types of metabolic and morphological alterations according to the Marrakech classification. Antivir Ther 2000;5(Suppl 5):59.
42. Lichtenstein KA, Delaney KM, Ward DJ, Palella FJ. Clinical factors associated with incidence and prevalence of fat atrophy and accumulation. Antivir Ther 2000;5(Suppl 5):61.
43. Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001;15:231-9.
44. Gervasoni C, Ridolfo AL, Trifiro G. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999;13:465-71.
45. Galli M, Veglia F, Angarano G, et al. Gender differences in antiretroviral drug-related adipose tissue alterations: Women are at higher risk than men and develop particular lipodystrophy patterns. J Acquir Immune Defic Syndr 2003;34:58-61.
46. Dezii CM, Lichtenstein KA, Maa J, Hodder SL. Significant correlation between low nadir CD4 and the incidence of fat wasting but not lipodystrophy without fat wasting. Antiviral Ther 2003;8:L55.
47. Raghavan S, Mullin C, Bartsch G, et al. Association between HIV disease characteristics with total and regional body composition levels in antiretroviral naive men and women. Antivir Ther 2003;8:L66.
48. Bogner JR, Vielhauer V, Beckmann RA, et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr 2001;27:237-44.
49. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000;14:1309-16.
50. Dubé MP, Zackin R, Tebas P, et al. Prospective study of regional body composition in antiretroviral-naive subjects randomized to receive zidovudine+lamivudine or didanosine+stavudine combined with nelfinavir, efavirenz or both: A5005s, a substudy of ACTG 384. Antivir Ther 2002;7:L18.
51. Benson JO, McGhee K, Coplan P, et al. Fat redistribution in indinavir-treated patients with HIV infection: A review of postmarketing cases. J Acquir Immune Defic Syndr 2000;25:130-9.
52. Chêne G, Angelini E, Cotte L, et al. Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis 2002;34:649-57.
53. Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1 infected patients: Results of a substudy from a comparative trial. AIDS 2002;16:2447-54.
54. van der Valk M, Casula M, Ruiter JP, et al. Relation between Use of Nucleoside Reverse Transcriptase Inhibitors, Mitochondrial DNA Depletion, and Severity of Lipoatrophy: Results from a Randomized Trial Comparing Stavudine and Zidovudine-based Antiretroviral Therapy [abstract 739]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Virginia: Foundation for Retrovirology and Human Health, 2003:323.
55. Law M, Emery S, French M, Carr A, Chuah J, Cooper D. Lipodystrophy and metabolic abnormalities in a cross-sectional study of participants in randomized controlled studies of combination antiretroviral therapy. Antiviral Ther 2000;5(Suppl 5):128.
56. Goujard C, Lascaux AS, Dulioust A, et al. Lipodystrophy in PI-naive patients treated with RTI combinations: Frequency and risk factors, [abstract 20]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco). Virginia: Foundation for Retrovirology and Human Health, 2000:79.
57. Scarsella AJ, Dieterich DT, Graham NM, et al. Predictors of Lipodystrophy in HIV-Infected Patients from the CHORUS Observational Cohort [abstract 1286]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington: American Society for Microbiology, 2000:313.
58. Martinez E, Milinkovic A, Garcia M, et al. Risk of lipodystrophy in HIV-1-infected patients receiving highly active antiretroviral therapy not containing protease inhibitors: A prospective cohort study [abstract ThPeB7355]. In: Program and abstracts of the XIV International AIDS Conference (Barcelona). Barcelona: Fundació Barcelona SIDA, 2002.
59. Lauenroth-Mai E, Schlote F. HIV-associated lipodystrophy syndrome: LioN-HAART cohort (lipodystrophy in patients on nucleoside-based HAART). Highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002;31:253-5.
60. Domingo P, Sambeat MA, Pérez A, Ordonez J, Rodriguez J, Vazquez G. Fat distribution and metabolic abnormalities in HIV-infected patients on first combination antiretroviral therapy including stavudine or zidovudine: Role of physical activity as a protective factor. Antivir Ther 2003;8:223-31.
61. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: A prospective cohort study. Lancet 2001;357:592-8.
62. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000;22:685-708.
63. Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy. AIDS 1999;13:2311-2.
64. Walker UA, Brinkman K. NRTI-induced mitochondrial toxicity as a mechanism for HAART related lipodystrophy: Fact or fiction? HIV Med 2001;2:163-5.
65. Chen CH, Vasquez-Padua M, Cheng YC. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implications for delayed toxicity. Mol Pharmacol 1991;39:625-8.
66. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway. AIDS 1998;12:1735-44.
67. Longley MJ, Ropp PA, Lim SE, Copeland WC. Characterization of the native and recombinant catalytic subunit of human DNA polymerase gamma: Identification of residues critical for exonuclease activity and dideoxynucleotide sensitivity. Biochemistry 1998;37:10529-39.
68. Bastard JP, Caron M, Vidal H, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002;359:1026-31.
69. Murata H, Hruz PW, Mueckler M. Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS 2002;16:859-63.
70. Ledru E, Christeff N, Patey O, de Truchis P, Melchior JC, Gougeon ML. Alteration of tumour necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: Contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood 2000;95:3191-8.
71. Albu JB, Johnson J, Engelson ES, Ionescu G, Sheikhan J, Kotler DP. Studies of subcutaneous adipose tissue (SAT) in HIV+ subjects with and without lipodystrophy [abstract ThPeB7357]. In: Program and abstracts of die XIV International AIDS Conference (Barcelona). Barcelona: Fundació Barcelona SIDA 2002.
72. Pettit R, Muurahainen N, Falutz J, et al. HIV-1-related truncal obesity: A comparison of physician and patient diagnosis in the SALSA (Self-Ascertained Lipodystrophy Syndrome Assessment) [abstract 651]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Virginia: Foundation for Retrovirology and Human Health, 1999:190.
73. Schwenk A, Breuer P, Kremer G, Ward L. Clinical assessment of HIV-associated lipodystrophy syndrome: Bioelectrical impedance analysis, anthropometry and clinical scores. Clin Nutr 2001;20:243-9.
74. Macallan D, Hodgetts V, Cotton J. Conventional anthropometric measures are poor reflectors of clinical lipodystrophy [abstract WePeB4246]. In: Program and abstracts of the XIII International AIDS Conference (Durban). Stockholm: International AIDS Society, 2000.
75. Shevitz AH, Knox TA. Nutrition in the era of highly active antiretroviral therapy. Clin Infect Dis 2001;32:1769-75.
76. Jacobson DL, Knox T, Gorbach S, Wanke C. Evolution of fat atrophy (FA) and fat deposition (FD) over 1 year in a cohort of HIV-infected men and women. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Virginia: Foundation for Retrovirology and Human Health, 2002:685-T.
77. Kotler D, Engelson E, Heymsfield S, Chang P, Muurahainen N, Gertner J. Anthropometric criteria define visceral fat excess in patients with HIV-associated adipose redistribution syndrome (HARS), a subset of HIV lipodystrophy [abstract 688-T]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Virginia: Foundation for Retrovirology and Human Health, 2002:304.
78. Kotler D, Thompson M, Chang P, Gertner J, Muurahainen N; for the STARS Trial Investigator Group. Anthropometric measures are poor surrogate markers for monitoring change in abdominal adiposity in HIV patients treated with growth hormone. Antivir Ther 2002;7:L49.
79. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999;13:1659-67.
80. Thöni G, Reynes J, Mercier J, et al. Do lipoatrophic HIV1-infected patients present the same metabolic abnormalities as those with abdominal fat accumulation? [abstract ThOrB757]. In: Program and abstracts of the XIII International AIDS Conference (Durban). Stockholm: International AIDS Society, 2002.
81. Rodriguez-Guardado A, Maradona JA, Carton JA, Asensi V. Triglyceride increase can predict lipodystrophy in HIV patients under highly active antiretroviral therapy. AIDS 2002;16:1434-6.
82. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis and prediction of HIV protease inhibitor (PI)-induced lipodystrophy and impaired glucose tolerance [abstract 641]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Virginia: Foundation for Retrovirology and Human Health, 1999:188.
83. Arpadi SM, Cuff PA, Horlick MB, Kotler DP, Wang J. Changes in regional body fat and serum triglycerides and cholesterol in HIV-infected children. Antivir Ther 2000;5(Suppl 5):14
84. White AJ, John M, Moore C, James IR, Nolan D, Mallal SA. Raised lactate levels are common and may be predictive of subcutaneous fat wasting. Antivir Ther 2000;5(Suppl 5):72.
85. Martinez E, Bianchi L, Garcia-Viejo MA, Bru C, Gatell JM. Sonographic assessment of regional fat in HIV-1-infected people. Lancet 2000;356:1412-3.
86. Viganè A, Bricalli D, Sala N, et al. HAART-associated changes in body fat distribution are detectable in HIV-infected children even in the absence of clinical evidence of lipodystrophy [abstract 681-T]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Virginia: Foundation for Retrovirology and Human Health, 2002:301.
87. Paton N, Ng Y-M, Chua Y-K, Aboulhab J, Karim F. Comparison of regional body composition changes in lipodystrophy with those of tuberculosis-related wasting [abstract 687-T]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Virginia: Foundation for Retrovirology and Human Health, 2002:304.
88. Seidell JC, Bakker CJ, van der Kooy K. Imaging techniques for measuring adipose-tissue distribution: A comparison between computed tomography and 1.5-T magnetic resonance. Am J Clin Nutr 1990;51:953-7.
89. Schoen RE, Thaete FL, Sankey SS, Wessfeld JL, Kuller LH. Sagittal diameter in comparison with single slice CT as a predictor of total visceral adipose tissue volume. Int J Obes Relat Metab Disord 1998;22:338-42.
90. Hatano H, Miller KD, Yoder CP, et al. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy. AIDS 2000;14:1935-42.
91. Roubenoff R, McDermott A, Weiss L, et al. Short-term progressive resistance training increases strength and lean body mass in adults infected with human immunodeficiency virus. AIDS 1999;13:231-9.
92. Jones SP, Doran DA, Leatt PB, Maher B, Pirmohamed M. Short-term exercise training improves body composition and hyperlipidaemia in HIV-positive individuals with lipodystrophy. AIDS 2001;15:2049-51.
93. Thoni GJ, Fedou C, Renard E, Mercier J, Reynes J, Varray A. Reducing visceral fat accumulation and blood lipid disorders in HIV-infected patients with lipodystrophy by an aerobic training program [abstract B10306]. In: Program and abstracts of the XIV International AIDS Conference (Barcelona). Barcelona: Fundació Barcelona SIDA, 2002.
94. Yarasheski KE, Tebas P, Stanerson B, et al. Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy [abstract 54]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco). Virginia: Foundation for Retrovirology and Human Health, 2000:85.
95. Hendricks KM, Dong KR, Tang AM, et al. High-fiber diet in HIV-positive men is associated with lower risk of developing fat deposition. Am J Clin Nutr 2003;78:790-5.
96. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, April 7, 2005. Developed by the panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation, 〈http://www. aidsinfo.nih.gov/ guidelines/adult/AA_040705.pdf〉 (Version current at August 4, 2005).
97. Martinez E, Garcia-Viejo MA, Blanco JL, et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis 2000;31:1266-73.
98. Bonnet E, Yovanovitch JD, Mularczyk MB, et al. Switching from protease inhibitors to efavirenz does not improve clinical lipodystrophy and hyperlipidaemia in HIV-infected patients [abstract 1538]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington: American Society for Microbiology, 2000:326.
99. Viciana P, Alarcon A, Martin D, et al. Partial improvement of lipodystrophy after switching from HIV-1 protease inhibitors (PI) to efavirenz (EFV) [abstract 48]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco). Virginia: Foundation for Retrovirology and Human Health, 2000:84.
100. Estrada V, De Villar NG, Larrad MT, Lopez AG, Fernandez C, Serrano-Rios M. Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy. Clin Infect Dis 2002;35:69-76.
101. Moyle GJ, Baldwin C, Dent N, Gazzard B. Management of indinavir-associated lipodystrophy by substitution with efavirenz in virologically controlled HIV+ persons [abstract 669]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Virginia: Foundation for Retrovirology and Human Health, 1999:193.
102. Lafon E, Bani Sadr F, Chandemerle C, et al. LIPSTOP study: Evolution of clinical lipodystrophy (LD), blood lipids, visceral (VAT) and subcutaneous (SAT) adipose tissue after switching from protease inhibitor (PI) to efavirenz (EFV) in HIV-1-infected patients [abstract 1535]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, District of Columbia; American Society for Microbiology, 2000:325.
103. Gharakhanian S, Salhi Y, Adda N, Vigoureux C, Capeau J, Rozenbaum W. Identification of fat redistribution/metabolic anomalies in a cohort treated by 2 NRTIs + 1 PI, and absence of significant modification following PI substitution [abstract 46]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco). Virginia: Foundation for Retrovirology and Human Health, 2000:84
104. Knechten H, Sturner KH, Hohn C, Braun P. Switch to efavirenz in a protease inhibitor containing regimen. HIV Clin Trials 2001;2:200-4.
105. Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ, Oonzalez-Lahoz J. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000;14:807-12.
106. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999;13:805-10.
107. Tebas P, Yarasheski K, Henry K, et al. Evolution of multiple metabolic parameters after the switch of protease inhibitors to nevirapine [abstract ThPpB1485]. In: Program and abstracts of the XIII International AIDS Conference (Durban). Stockholm: International AIDS Society, 2000.
108. Ruiz L, Negredo E, Domingo P, et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr 2001;27:229-36.
109. Rozenbaum W, Delfraissy JF, Bentata M, de Truchis P, Antoun Z. Metabolic and clinical evaluation of lipodystrophy 48 weeks after switching from 2 NRTI/PI to 2 NRTI/abacavir French substudy, CNA 30017. Antivir Ther 2000;5(Suppl 5):76.
110. Lafeuillade A, Clumeck N, Mallolas J, et al. Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to trizivir versus continued HAART: The Trizal study. HIV Clin Trials 2003;4:37-43.
111. Negredo E, Cruz L, Paredes R, et al. Virological, immunological, and clinical impact of switching from protease inhibitiors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis 2002;34:504-10.
112. Fisac C, Fumero E, Crespo M, et al. Metabolic and body composition changes in patients switching from a protease inhibitor-containing regimen to Abacavir (ABC), Efavirenz (EFV) or Nevirapine (NVP). Twelve-month results of a randomized study (LIPNEFA) [abstract ThPeB 7354]. In: Program and abstracts of the XIV International Aids Conference (Barcelona). Barcelona: Fundació Barcelona SIDA, 2002.
113. Casado JL, Arrizabalaga J, Antela A, et al; for the BEGIN Study. Long-term efficacy and tolerance of switching the protease inhibitor for non-nucleoside reverse transcriptase inhibitors: A 52-week, multicenter, prospective study [abstract 673]. In: Program and abstracts of the 8th Conference on Retrovirus and Opportunistic Infections (Chicago). Virginia: Foundation for Retrovirology and Human Health, 2001:246.
114. Carr A, Workman C, Smith DE, et al; Mitochondrial Toxicity (MITOX) Study Group. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: A randomized trial. JAMA 2002;288:207-15.
115. Martin A, Smith DE, Carr A, et al; Mitochondrial Toxicity Study Group. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: The MITOX Extension Study. AIDS 2004;18:1029-36.
116. McComsey GA, Ward DJ, Hessenthaler SM, et al; Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL; ESS40010) Study Team. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: The results of the TARHEEL study. Clin Infect Dis 2004;38:263-70.
117. Saint-Marc T, Partisani M, Poizot-Martin I, Touraine JL. Reversibility of peripheral fat wasting on stopping stavudine therapy [abstract 52]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco). Virginia: Foundation for Retrovirology and Human Health, 2000:85.
118. Garcia-Benayas T, Blanco F, de la Cruz JJ, Soriano V, Gonzalez-Lahoz J. Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy. AIDS 2003;17:921-4.
119. Carr A, Hudson J, Chuah J. HIV protease inhibitor substitution in patients with lipodystrophy: A randomized, controlled, open-label, multicentre study. AIDS 2001;15:1811-22.
120. Bickel M, Rickerts V, Klauke S, et al. The Protra study: To evaluate the safety and efficacy of abacavir (ABC) and efavirenz (EFV) when substituted for a PI in HIV-1-infected subjects treated with 2 NRTIs and a PI with plasma HIV-RNA levels below the limit of assay quantification [abstract TuPeB3210]. In: Program and abstracts of the XIII International AIDS Conference (Durban). Stockholm: International AIDS Society, 2000.
121. John M, McKinnon EJ, James IR, et al. A randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquit Immune Defic Syndr 2003;33:29-33.
122. Moyle GJ, Baldwin C, Langroudi B, Mandalia S, Gazzard BG. A 48-week, randomized, open-label comparison of three abacavir based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquit Immune Defic Syndr 2003;33:22-8.
123. Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht M. Recombinant human growth hormone improves the fat redistribution syndrome in patients with HIV. AIDS 1999;13:2099-103.
124. Engelson ES, Glesby MJ, Mendez D, et al. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquit Immune Defic Syndr 2002;30:379-91.
125. Torres R. Long-term fellow-up of patients with HARS receiving rh-Gh: Another dilemma of early versus delayed intervention? [abstract WePeB4234]. In: Program and abstracts of the XIII International AIDS Conference (Durban). Stockholm: International AIDS Society, 2000.
126. Lo JC, Mulligan K, Noor MA, et al. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 2001;86:3480-7.
127. Kotler D, Thompson M, Grunfeld C, et al. Growth hormone (Serostimreg) significantly reduces visceral adipose tissue (VAT) accumulation and non-HDL cholesterol [abstract LbOr18]. In: Program and abstracts of the XIV International AIDS Conference (Barcelona). Barcelona: Fundació Barcelona SIDA, 2002.
128. Dieterich D, Aymat R, Braun J, et al. Incidence of body habitus changes in a cohort of 725 HIV-infected patients [abstract 674]. In: Program and
129. Hadigan C, Corcoron C, Stanley K, Piecuch S, Klibanski A, Grinspoon S. Fasting hyperinsulinemia in HIV-infected men: Relationship to body composition, gonadal function and protease inhibitor use. J Clin Endocrinol Metab 2000;85:35-41.
130. Visnegarwala F, Maldonado MR. Use of PPAR-gamma modulator rosiglitazone in normoglycemic patients with HIV lipodystrophy syndrome. Antivir Ther 2001;6:82.
131. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy: A randomized, controlled trial. Ann Intern Med 2004;140:786-94.
132. Calmy A, Hirscel B, Hans D, Karsegard VL, Meier CA. Glitazones in lipodystrophy syndrome induced by HAART. AIDS 2003;17:770-2.
133. Sutinen J, Häkkinen A-M, Westerbacka J, et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy - A randomized, double-blind, placebo-controlled study. Antivir Ther 2003;8:199-207.
134. Carr A, Workman C, Carey D, et al; Rosey investigators. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: Randomised, double-blind, placebo-controlled trial. Lancet 2004;363:429-38.
135. Saint-Marc T, Touraine JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy [abstract 672]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Virginia: Foundation for Retrovirology and Human Health, 1999.
136. Martinez E, Domingo P, Ribera E, et al. Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors. Antivir Ther 2003;8:403-10.
137. Hadigan C, Rabe J, Grinspoon S. Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2002;87:4611-15.
138. Mauss S, Schmutz O. L-Carnitine in the treatment of HIV-associated lipodystrophy. HIV Med 2001;2:59-60.
139. Wolfort FG, Cetrulo CL Jr, Nevarre DR. Suction-assisted lipectomy for lipodystrophy syndromes attributed to HIV-protease inhibitor use. Plast Reconstr Surg 1999;104:1814-20.
140. Chastain MA, Chastain JB, Coleman WP. HIV lipodystrophy: Review of the syndrome and report of a case treated with liposuction. Dermatol Surg 2001;27:497-500.
141. Piliero PJ, Hubbard M, King J, Faragon JJ. Use of ultrasonography- assisted liposuction for the treatment of human immunodeficiency virus-associated enlargement of the dorsocervical fat pad. Clin Infect Dis 2003;37:1374-7.
142. Ponce-de Leon S, Iglesias M, Ceballos J, Ostrosky-Zeichner L. Liposuction for protease inhibitor-associated lipodystrophy. Lancet 1999;353:1244.
143. Lafaurie M, Dolivo J, Boulu D, Madelaine I, Molina JM. Treatment of HIV-associated lipoatrophy of the face with intradermal injections of polylactic acid [abstract 704-T]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Virginia: Foundation for Retrovirology and Human Health, 2002:310.
144. Levan P, Nguyen TH, Lallemand F, et al. Correction of facial lipoatrophy in HIV-infected patients on highly active antiretroviral therapy by injection of autologous fatty tissue. AIDS 2002;16:1985-7.
145. Guaraldi G, De Fazio D, Orlando G, et al. Autologous fat transfer for treating facial wasting in HIV fat redistribution syndrome [abstract 722]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Virginia: Foundation for Retrovirology and Human Health, 2003:316.
146. Strauch B, Baum T, Robbins N. Treatment of HIV-associated lipodystrophy with dermafat graft transfer to the malar area. Plast Reconstr Surg 2004;113:363-70.
147. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: Comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002;46:716-23.
148. Gallant J, Staszewski S, Poxniak A, et al. Favorable lipid and mitochondrial (mt) DNA profile for tenofovir disoproxil fumarate (TDF) compared to stavudine (d4T) in combination with lamivudine (3TC) and efavirenz (EFV) in antiretroviral therapy (ART) naïve patients: A 48-week interim analysis [abstract LB-2]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington: American Society for Microbiology, 2002.
149. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S; AI424-007 Clinical Trial Group. Results of a phase 2 clinical trial at 48 weeks (AI424-007): A dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003;32:18-29.
150. Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002;346:570-8.